Actinium presents first‑in‑human Phase 1 data for non‑PSMA radiotherapy ATNM‑400 in prostate cancer
Actinium Pharmaceuticals announced early Phase 1 results for ATNM‑400, a first‑in‑class Actinium‑225 antibody radioconjugate that targets a non‑PSMA antigen in metastatic castration‑resistant prostate cancer. The study evaluated a Zirconium‑89‑labeled version to assess safety, biodistribution and dosimetry, with PET imaging used to measure tumor uptake. The data were presented orally at the 39th Annual Congress of the European Association of Nuclear Medicine in Vienna. Company chairman and CEO Sandesh Seth said the findings mark an important milestone for the program and for prostate‑cancer treatment beyond PSMA.
Why it matters
The company said the early clinical data support advancing ATNM‑400 to later‑stage development, which could expand its pipeline and future revenue potential. (The company’s statement is and.)
Key facts
- 1Actinium announced early Phase 1 trial results for ATNM‑400 in metastatic castration‑resistant prostate cancer. stocktitan.net
- 2The trial evaluated Zirconium‑89‑labeled ATNM‑400 to assess safety, biodistribution and dosimetry. stocktitan.net
- 3ATNM‑400 is a first‑in‑class Actinium‑225 antibody radioconjugate targeting a non‑PSMA antigen. prnewswire.com
- 4The oral presentation was scheduled for Monday, October 19, 2026, 4:45–6:15 p.m. CEST at the EANM 2026 Congress in Vienna, Austria. prnewswire.com
- 5Sandesh Seth, Actinium’s Chairman and CEO, called the data an important milestone for the company and for prostate‑cancer treatment beyond PSMA. stocktitan.net
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.